dr. peters discusses ongoing research with trastuzumab deruxtecan in nsclc
Published 4 years ago • 238 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
0:56
dr. rizvi on the utility of trastuzumab deruxtecan in nsclc
-
1:05
dr. pegram on pertuzumab plus trastuzumab and chemotherapy in breast cancer
-
2:31
dr. peter beitsch on pertuzumab in luminal subtype breast cancer
-
5:45
#esmo21 expert video report on targeting in her2-positive metastatic breast and lung cancers
-
1:21
dr. park on the benefit of trastuzumab deruxtecan in her2 breast cancer
-
2:14
dr. pegram on sequencing therapies in her2-positive breast cancer
-
1:28
dr. peter beitsch on pertuzumab in the luminal subtype of her2-positive breast cancer
-
1:10
the birch trial data discussed by dr peters
-
1:12
dr. pegram on challenges in neoadjuvant treatment for her2-positive breast cancer
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
1:29
tuxedo-1: trastuzumab deruxtecan for the treatment of her2-positive breast cancer brain metastases
-
2:24
ds-8201 pembro in patients her2 breast and nsclc
-
25:11
trastuzumab deruxtecan for her2-low metastatic breast cancer | dr. jitendra pahlajani
-
7:30
#esmo21 expert video report on her2-positive metastatic breast cancer
-
2:09
the evolution of her2 targeting in metastatic breast breast cancer
-
1:45
strategies to target her2 in lung cancer
-
1:32
dr. singh on dose dense acthp in her2 breast cancer
-
26:42
the issue with elle macpherson’s holistic treatment for breast cancer | extra minutes
-
1:31
dr. pegram on margetuximab plus chemo in her2 breast cancer